Neovasc Inc

Neovasc — Investor Presentation (January 2015)

22 slides from Neovasc's investor presentation, January 2015

  1. Slide 1: Neovasc Inc. Equity Offering

    Neovasc Inc. Equity Offering Alexei Marko, CEO Chris Clark, CFO January 2015

  2. Slide 2: Forward-looking statements

    Forward-looking statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward- lo

  3. Slide 3: Cardiovascular products for refractory angina and mitral valve disease

    Cardiovascular products for refractory angina and mitral valve disease Commercial products and established revenues 3

  4. Slide 4: Management and Board

    Management and Board Management ALEXEI MARKO CHRIS CLARK BRIAN MCPHERSON CHIEF EXECUTIVE OFFICER, DIRECTOR CHIEF FINANCIAL OFFICER CHIEF OPERATING OFFICER Almost 20 years experience in Almost 20 years finance and More than 20 years experience in medical device field; Neovasc accounting experience me

  5. Slide 5: 3 product lines targeting significant markets

    3 product lines Targeting 3 significant markets Tiara™ Reducer™ Biological Tissue Transcatheter mitral Transcatheter device for Proprietary biological valve replacement refractory angina tissue products for (investigational) (CE marked) implantable medical devices (commercial) 5

  6. Slide 6: Tiara Transcatheter Mitral Valve

    Tiara™ Transcatheter Mitral Valve

  7. Slide 7: Minimally invasive device under development for mitral regurgitation

    Minimally invasive device under development for millions of patients who experience mitral regurgitation as a result of mitral heart valve disease 7

  8. Slide 8: Mitral Valve Regurgitation (MR)

    Mitral Valve Regurgitation (MR) A serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy M I T R AL R E G U RG I TAT I O N VALVE D OES N OT FU LLY C LOS E Results in: • heart failure • death 8

  9. Slide 9: Tiara Addressable market opportunity

    Tiara Addressable market opportunity • Estimated that in 2015, ~5.9 million people will suffer from MR in the US and EU • ~40% of these MR patients in US suffer from significant MR • A significant percentage of patients with severe MR are not good candidates for conventional surgical treatment EuroI

  10. Slide 10: Tiara: novel investigational transcatheter mitral valve replacement

    Tiara A novel investigational transcatheter Mitral Valve replacement REPLACES THE DISEASED VALVE • Design is specific to mitral anatomy • Does not obstruct left ventricular outflow tract (LVOT) • Quick and repeatable implantation procedure • No need for cardiac bypass 10

  11. Slide 11: Tiara: first human implant January 2014

    Tiara January 2014 - first human implant of Tiara Conducted by physicians at St. Paul’s Hospital, Vancouver, Canada Five patients treated to date (four pursuant to compassionate use exemptions, one clinical study subject) EXCELLENT RESULTS FROM FIRST CASES • No procedural complications • Complete re

  12. Slide 12: TIARA-I early feasibility study

    TIARA- I Multinational, multicenter early feasibility study in the US, Canada, EU • Observational study of high-risk (operable) patients • Co-Chairs of Study Committee: • Dr. Martin Leon • Dr. Anson Cheung • Enroll up to 30 patients • Participating centers include: Columbia University Medical Center

  13. Slide 13: Reducer Refractory Angina Therapy

    Reducer™ Refractory Angina Therapy

  14. Slide 14: Refractory Angina

    Refractory Angina Debilitating condition with limited treatment options ~645,000 (estimated) refractory angina patients in the US who are potential candidates substantially larger population of “recurrent” angina patients C AU S E D BY I N AD E Q UAT E B LO O D F LOW TO AR E AS O F T HE HEART M US C

  15. Slide 15: Reducer 20 minute catheter-based procedure

    Reducer 20 minute catheter-based procedure • Implanted in the coronary sinus (large vein in heart) • Hourglass shape modulates flow of blood in the heart to elevate CS pressure • Re-distributing blood and increasing flow to ischemic areas in the endocardium • CE marked Reducer modulates flow to elev

  16. Slide 16: COSIRA study primary endpoint achieved

    Reducer COSIRA study primary endpoint achieved Double-blind, randomized, sham-controlled, multicenter prospective trial • n = 104 patients at 11 clinical investigation sites • Improvement of ≥2 angina CCS classes (primary endpoint) occurred approximately 2.3x more frequently in Reducer group (P =0.0

  17. Slide 17: Reducer expected next steps

    Reducer Expected next steps • Expand enrollment in European Registries • File IDE application and initiate US IDE Study required for FDA approval • Introduce product into pilot centers in Europe • Explore full commercial launch in EU 17

  18. Slide 18: Our Biological Tissue Business

    Our Biological Tissue Business Working with industry customers to improve patient care

  19. Slide 19: Biological Tissue

    Biological Tissue Proprietary process with 25+ year implant history • Implantable tissue from animal pericardium • Retains mechanical characteristics of natural tissue • Used in implantable medical devices including transcatheter heart valves • Represents 100% of Neovasc’s current revenues 19

  20. Slide 20: Corporate Overview

    Corporate Overview • Current cash and cash equivalents / investments position, as of September 30, 2014 of ~$21.7m (low long-term debt) • Listed on TSX and NASDAQ 20

  21. Slide 21: Objectives

    Objectives • Tiara Program – Complete TIARA-I enrollment in 2015 – Activities to support CE mark application – Activities to support US IDE application • Reducer Program – Initiate US FDA trial in 2015 – Preparing for EU product launch • Tissue Business – Continue to support infrastructure and devel

  22. Slide 22: Thank you

    Thank you Alexei Marko, CEO Chris Clark, CFO January 2015

Neovasc — Investor Presentation (January 2015) on 6ix